Damian James Mole

Damian James Mole

Auto-generated profile, based on publicly available information

Damian James Mole

Centre for Inflammation Research, Institute for Regeneration and Repair, Edinburgh Bioquarter, The University of Edinburgh

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2016 in Science
Verified
Journal Article
Closed access
PDF file
RDRodger Duffin
Rodger Duffin
RORichard A. O’cOnnor
Richard A. O’cOnnor
SCSiobhan Crittenden
Siobhan Crittenden
TFThorsten Forster
Thorsten Forster
CYCunjing Yu
Cunjing Yu
CYChengcan Yao
Chengcan Yao
A prostaglandin barrier to inflammation: Blood-borne bacterial infections and severe trauma can send the immune system into overdrive, causing it to pump out inflammatory mediators, sometimes at lethal doses. Duffin et al. now report on a role for prostaglandins in keeping systemic inflammation in check. Systemic inflammation correlates with decreased production of the prostaglandin E2 (PGE2). Blocking PGE2 signaling in mice led to severe inflammation associated with the translocation of gut bacteria. PGE2 acts on innate lymphoid cells, which produce interleukin-22, a secreted protein that helps promote intestinal integrity. Science , this issue p. 1333

11 January 2016 in Nature Medicine
Verified
Journal Article
Open access
PDF file
DMDamian J Mole
Damian J Mole
SWScott P Webster
Scott P Webster
IUIain Uings
Iain Uings
XZXiaozhong Zheng
Xiaozhong Zheng
MBMargaret Binnie
Margaret Binnie
JIJohn P Iredale
John P Iredale
Blocking the enzyme KMO with a small molecule reduces the levels of toxic tryptophan metabolites and reduces multiple extrapancreatic organ failure in a rat model of acute pancreatitis. Acute pancreatitis (AP) is a common and devastating inflammatory condition of the pancreas that is considered to be a paradigm of sterile inflammation leading to systemic multiple organ dysfunction syndrome (MODS) and death1,2. Acute mortality from AP-MODS exceeds 20% (ref. 3), and the lifespans of those who survive the initial episode are typically shorter than those of the general population4. There are no specific therapies available to protect individuals from AP-MODS. Here we show that kynurenine-3-monooxygenase (KMO), a key enzyme of tryptophan metabolism5, is central to the pathogenesis of AP-MODS. We created a mouse strain that is deficient for Kmo (encoding KMO) and that has a robust biochemical phenotype that protects against extrapancreatic tissue injury to the lung, kidney and liver in experimental AP-MODS. A medicinal chemistry strategy based on modifications of the kynurenine substrate led to the discovery of the oxazolidinone GSK180 as a potent and specific inhibitor of KMO. The binding mode of the inhibitor in the active site was confirmed by X-ray co-crystallography at 3.2 Å resolution. Treatment with GSK180 resulted in rapid changes in the levels of kynurenine pathway metabolites in vivo, and it afforded therapeutic protection against MODS in a rat model of AP. Our findings establish KMO inhibition as a novel therapeutic strategy in the treatment of AP-MODS, and they open up a new area for drug discovery in critical illness.

1 May 2024 in Nature
Verified
Journal Article
Open access
PDF file
KMK. P. Matchett
K. P. Matchett
JWJ. R. Wilson-Kanamori
J. R. Wilson-Kanamori
JPJ. R. Portman
J. R. Portman
CKC. A. Kapourani
C. A. Kapourani
FFF. Fercoq
F. Fercoq
NHN. C. Henderson
N. C. Henderson
The liver has a unique ability to regenerate1,2; however, in the setting of acute liver failure (ALF), this regenerative capacity is often overwhelmed, leaving emergency liver transplantation as the only curative option3–5. Here, to advance understanding of human liver regeneration, we use paired single-nucleus RNA sequencing combined with spatial profiling of healthy and ALF explant human livers to generate a single-cell, pan-lineage atlas of human liver regeneration. We uncover a novel ANXA2+ migratory hepatocyte subpopulation, which emerges during human liver regeneration, and a corollary subpopulation in a mouse model of acetaminophen (APAP)-induced liver regeneration. Interrogation of necrotic wound closure and hepatocyte proliferation across multiple timepoints following APAP-induced liver injury in mice demonstrates that wound closure precedes hepatocyte proliferation. Four-dimensional intravital imaging of APAP-induced mouse liver injury identifies motile hepatocytes at the edge of the necrotic area, enabling collective migration of the hepatocyte sheet to effect wound closure. Depletion of hepatocyte ANXA2 reduces hepatocyte growth factor-induced human and mouse hepatocyte migration in vitro, and abrogates necrotic wound closure following APAP-induced mouse liver injury. Together, our work dissects unanticipated aspects of liver regeneration, demonstrating an uncoupling of wound closure and hepatocyte proliferation and uncovering a novel migratory hepatocyte subpopulation that mediates wound closure following liver injury. Therapies designed to promote rapid reconstitution of normal hepatic microarchitecture and reparation of the gut–liver barrier may advance new areas of therapeutic discovery in regenerative medicine.

16 September 2009 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
SBS. A. Badger
S. A. Badger
RBR. Barclay
R. Barclay
PCP. Campbell
P. Campbell
DMD. J. Mole
D. J. Mole
TDT. Diamond
T. Diamond

12 February 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
SCSiobhan Crittenden
Siobhan Crittenden
MGMarie Goepp
Marie Goepp
JPJolinda Pollock
Jolinda Pollock
CRCalum T Robb
Calum T Robb
DSDanielle J Smyth
Danielle J Smyth
CYChengcan Yao
Chengcan Yao
PGE 2 inhibits T regs and promotes intestinal inflammation through actions on mononuclear phagocytes and the gut microbiota.

19 July 2013 in Hepatology
Verified
Journal Article
Open access
PDF file
Jonathan FallowfieldJonathan Fallowfield
Jonathan Fallowfield
AHAnnette L. Hayden
Annette L. Hayden
VSVictoria K. Snowdon
Victoria K. Snowdon
RARebecca L. Aucott
Rebecca L. Aucott
BSBen M. Stutchfield
Ben M. Stutchfield
JIJohn P. Iredale
John P. Iredale
Active myofibroblast (MF) contraction contributes significantly to the increased intrahepatic vascular resistance that is the primary cause of portal hypertension (PHT) in cirrhosis. We sought proof of concept for direct therapeutic targeting of the dynamic component of PHT and markers of MF activation using short-term administration of the peptide hormone relaxin (RLN). We defined the portal hypotensive effect in rat models of sinusoidal PHT and the expression, activity, and function of the RLN-receptor signaling axis in human liver MFs. The effects of RLN were studied after 8 and 16 weeks carbon tetrachloride intoxication, following bile duct ligation, and in tissue culture models. Hemodynamic changes were analyzed by direct cannulation, perivascular flowprobe, indocyanine green imaging, and functional magnetic resonance imaging. Serum and hepatic nitric oxide (NO) levels were determined by immunoassay. Hepatic inflammation was assessed by histology and serum markers and fibrosis by collagen proportionate area. Gene expression was analyzed by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and western blotting and hepatic stellate cell (HSC)-MF contractility by gel contraction assay. Increased expression of RLN receptor (RXFP1) was shown in HSC-MFs and fibrotic liver diseases in both rats and humans. RLN induced a selective and significant reduction in portal pressure in pathologically distinct PHT models, through augmentation of intrahepatic NO signaling and a dramatic reduction in contractile filament expression in HSC-MFs. Critical for translation, RLN did not induce systemic hypotension even in advanced cirrhosis models. Portal blood flow and hepatic oxygenation were increased by RLN in early cirrhosis. Treatment of human HSC-MFs with RLN inhibited contractility and induced an antifibrogenic phenotype in an RXFP1-dependent manner. Conclusion: We identified RXFP1 as a potential new therapeutic target for PHT and MF activation status. (HEPATOLOGY 2014;59:1492-1504)